Andrea K. Wahlquist Brown

212-373-3008awahlquistbrown@paulweiss.com

1285 Avenue of the Americas
New York, NY 10019-6064

Andrea Wahlquist Brown is a partner in Paul Weiss’s Executive Compensation Group. Wahlquist Brown has over 25 years of experience with complex and high-profile executive compensation matters arising in the fast-paced practice area of mergers & acquisitions. She advises on all aspects of executive compensation, employee benefits and governance matters, in a wide range of transactions involving public company, private equity, bankruptcy estate and creditor committee clients, with an emphasis on representing public companies in strategic mergers and spin-offs, as well as initial public offerings of public companies and advisory work for public company compensation committees. Wahlquist Brown also has represented some of the largest private equity sponsors in the acquisition, operation and disposition of their portfolio companies.

Lawdragon Honors

Honor	Year	Practice
The 2026 Lawdragon 500 Leading Corporate Employment Lawyers	2026	Executive Compensation & Benefits
The 2025 Lawdragon 500 Leading Corporate Employment Lawyers	2025	Executive Compensation & Benefits
The 2024 Lawdragon 500 Corporate Employment Lawyers	2024	Executive Compensation & Benefits
Lawdragon Releases Latest Guide to the Leading Corporate Employment Lawyers in America	2022	Executive Compensation & Benefits
Lawdragon's Leading Corporate Employment Lawyers of America	2021	Executive Compensation & Benefits
Lawdragon 500 Leading U.S. Corporate Employment Lawyers	2020	Executive Compensation & Benefits

Some of Wahlquist Brown's most recent experience includes:

Allergan in its $63 billion sale to AbbVie
Analog Devices in its $21 billion acquisition of Maxim Integrated Products
Funds managed by Apollo Global Management in their acquisition of the Accent Family of Companies
BCG Partners in its spin-off of Newmark Group
Brookfield Infrastructure Partners in its $775 million acquisition of Cyxtera in connection with its chapter 11 case
Inhibrx in the $2.2 billion sale of INBRX-101 to Sanofi and the related spin-off of Inhibrx’s non-101 assets and liabilities, non-101 discovery pipeline and its corporate infrastructure, to create a new publicly traded company known as Inhibrx Biosciences
Jazz Pharmaceuticals in its $7.2 billion acquisition of GW Pharmaceuticals
MediPacific, a Foresite Capital Management company, in its acquisition of Pardes Biosciences
Medline Industries in its sale of a majority interest to a consortium made up Blackstone, Carlyle and Hellman & Friedman for $31 billion
Meritor in its $3.7 billion sale to Cummins
Neptune Retail Solutions in its take-private acquisition of Quotient Technology
ServiceMaster in its spin-off of Frontdoor
Tenneco in its $7.1 billion sale to affiliates of Apollo Global Management
Zendesk in its acquisition by a consortium of investors for $10.2 billion